TCT-754 Clinical and Left Ventricular Functional Outcomes Associated with Cardiac Biomarker Elevation after Transapical TAVR: A Sub-analysis from the PARTNER Trial  by Paradis, Jean-Michel et al.
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM
P
O
S
T
E
R
Sliterature search of studies on decision making in AS.Monte Carlo simulations were
performed to estimate the number of TAVR candidates in 19 European countries and
North America.
Results: Data from 7 studies (n¼9,723 subjects) were used.The prevalence of all AS
in the elderly was 12.4%(95%CI:6.6-18.2%),and the prevalence of severe AS was
3.4% (95%CI:1.1-5.7%).Among elderly with severe AS,75.6% (95%CI:65.8-85.4%)
were symptomatic,and 40.5% (95%CI:35.8-45.1%) of these patients were not treated
surgically.Of those,40.3% (95%CI:33.8-46.7%) received TAVR.Of the high-risk
patients,5.2% were candidates.Projections showed that there are approx. 189,836
(95%CI:80,281-347,372) TAVR candidates in the European countries and 102,558
(95%CI:43,612-187,002)in North America. Annually, there are 17,712 (95%CI:7,590-
32,691) new candidates in the EU and 9,189 (95%CI:3,898-16,682) in North America.Conclusions: With a pooled prevalence of 3.4%, the burden of disease among the
elderly due to severe AS is substantial.Under current indications,approx 290,000
elderly patients with severe AS are TAVR candidates.Nearly 27,000 patients become
eligible for TAVR annually.
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Background: Since commercialization in 2007, the number of transcatheter aortic
valve replacement (TAVR) procedures has grown exponentially. Despite the
encouraging results from randomized controlled trials and registries, there is anecdotal
evidence that the utilization of TAVR varies markedly across Europe. We sought to
examine the adoption of TAVR in Western Europe.
Methods: The adoption of TAVR was investigated in 11 European countries:
Germany, France, Italy, United Kingdom, Spain, Netherlands, Switzerland, Belgium,
Portugal, Denmark, and Ireland. Data were collected from two sources: (1) lead
physicians submitted nation-speciﬁc registry data; (2) an implantation-based TAVR-
market tracker. Population data were derived from European Union sources. TAVR
penetration in each nation was determined as a measure of actual TAVR use relative to
potential use.
Results: Between 2007 and 2011, 34,317 patients underwent TAVR. Considerable
variation in TAVR utilization existed across nations. Almost half of all implants were
performed in Germany (45.9%), with Italy (14.9%) and France (12.9%) the next most
frequent implanters. Ireland accounted for the smallest proportion of implants (0.4).
There was wide variation in the number of TAVR implants per million of population.
Germany (88.7) and Portugal (6.1) accounted for the highest and lowest number of
implants per million in 2011, respectively (meanstandard deviation: 32.9  24.9).
The number of centers performing TAVR increased 9-fold from 37 in 2007 to 342 in
2011. On average, there were 0.9  0.6 TAVR centers per million of population. TheJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrannual number of TAVR implants performed per center across nations also varied
widely (range:10 - 89). In 2011, we estimate that there were 28,400 living TAVR
recipients and 158,371 potential TAVR candidates in the 11 study nations. The
weighted average TAVR penetration rate was low: 17.9%. Germany (36.2%) and
Portugal (3.4%) had the highest and lowest TAVR penetration rates, respectively.
2012 - 2013 data will be available for presentation at TCT.
Conclusions: Despite the rapid adoption of TAVR in Europe, our ﬁndings indicate
that TAVR adoption varies markedly across Europe and remains greatly underutilized
in most nations.
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Background: Due to its speciﬁc design the selfexpanding 31mm CoreValve pros-
thesis (for annulus diameters between 26 and 29 mm) with its 4 mm landing zone can
be technically challenging. Thus the procedural results with this device might be
different from the ones with the smaller sizes. In addition the radial force of the nitinol
stent frame is larger in the 31mm device than in the smaller device sizes.
Methods: We retrospectively analyzed the procedural results of the 50 (out of over
600) patients in whom we implanted a 31mm selfexpanding CoreValve bioprosthesis
between 2011 and May 2013 and compared them to the 52 consecutive patients
implanted with a 29 mm device within the same period. Procedural results were
analyzed according to the VARC- criteria.
Results: Patients with large annuli and the 31 mm prosthesis had signiﬁcantly higher
rates of postinterventional pacemaker implantations (34% vs 19% ; p¼0.02) despite
similar implantation depths (6.9 mm vs. 6.6 mm ; p¼ns). Although not signiﬁcant,
there was a tendency towards increased rates of postinterventional aortic regurgitation
of more than mild (AR> grade 1)(14% vs.8%; p¼ns). In contrast major vascular
bleeding (2% vs. 2%), 30-day mortality (6% vs. 7.6%) and stroke/TIA (4% vs. 2 %)
were not different between the two groups.
Conclusions: Despite the technical challenges of the small (4 mm) landing zone,
procedural results with the 31mm device were similar to those with the smaller sizes of
the device. However, postinterventional pacemaker rates were signiﬁcantly higher in
the 31mm cohort despite comparable implantation depths, which might be the result of
the speciﬁc design of the device with its increased radial force.
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Background: Recent data demonstrated that transapical (TA) TAVR is associated
with post-procedural cardiac biomarker elevation in all patients (pts). The impact of
such myocardial damage after TA-TAVR remains uncertain.
Methods: Patients from the PARTNER trial (randomized and continued access
cohorts) treated with TA-TAVR who had baseline and 24h cardiac markers measured
(cardiac troponin I [cTnI] and/or creatine kinase-MB [CKMB]) were studied. Pts were
divided into tertiles (T1, T2, T3) based on the difference between the 24h and the
baseline values of each cardiac marker (DcTnI and DCKMB). Clinical and echocar-
diographic outcomes were compared between tertiles.
Results: A total of 339 pts (T1[-5.62 to 4.41 ng/mL])¼113, T2 [4.41 to 8.01 ng/
mL])¼113, T3 (8.10 to 70.13 ng/mL)¼113) were included in the DcTnI analysis,
while 415 pts (T1 [-27 to 9.3 U/L])¼138, T2 [9.4 to 21.6 U/L]¼139, T3 [22.0 to 438
U/L])¼139) were included in the DCKMB analysis. At 30 days, pts in the highest
tertile (T3) of cardiac biomarker elevation, compared with pts in the lowest tertile
(T1), had similar all-cause mortality rate (DcTnI: T3: 7.1% % vs T1: 6.2%, p¼0.7934;
DCKMB: T3: 12.3% vs T1: 6.5%, p¼0.0996) and cardiovascular mortality rate
(DcTnI: T3: 3.6% vs T1: 3.5%, p¼0.9987; DCKMB: T3: 5.9% vs T1: 4.4%,
p¼0.5629). At 1 year, although numerically higher in T3, there remained no signif-
icant difference between tertiles with respect to all-cause mortality (DcTnI: T3: 30.1%
vs T1: 22.7%, p¼0.1849; DCKMB: T3: 29.3% vs T1: 24.8%, p¼0.3704) (ﬁgure 1)
and cardiovascular mortality (DcTnI: T3: 16.8% vs T1: 14.9%, p¼0.7064; DCKMB:
T3: 17.0% vs T1: 16.6%, p¼0.9925). At 1 year, improvement of the New York Heart
Association (NYHA) functional class (DcTnI: p¼0.6599, DCKMB: p¼0.1734) andacts/POSTER/Aortic Valve Disease and Treatment B229
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Schange of left ventricular ejection fraction (LVEF) (DcTnI : p¼0.0874, DCKMB:
p¼0.9195) after TA-TAVR was similar between tertiles of both cardiac biomarkers.
Conclusions: In pts undergoing TA-TAVR in the PARTNER trial, a greater degree of
cTnI or CKMB elevation was not associated with signiﬁcantly higher all-cause or
cardiovascular mortality rates, at 30-days and at 1 year. Moreover, the degree of
myocardial injury had no impact on improvement in NYHA functional class or on
LVEF recovery.Invasive Hemodynamic and Clinical Variables Stratiﬁed by Valvuloarterial
Impedance Index Ratio
ZvaPost/ZvaPre <0.85
(n=38)
ZvaPost/ZvaPre>0.85
(n=47) p value
Zva-Post/Zva-Pre,
mean +SD
0.72 +0.1 1.1 +0.1 p<0.01
Aortic valve area, cm2 ,
mean, +SD
0.61 +0.2 0.67 +0.2 p¼0.78
Mean transvalvular
pressure gradient,
mmHg, mean, +SD
46.9 +17.2 42.7 +12.8 p¼0.84
Stroke volume index
,mmHg/mL/m2, mean
+SD
31.5 +9.5 32.5 +10.9 p¼0.94
Systolic arterial
pressure, mmHg, mean
+SD
131.1 +25.4 126 +28 p¼0.89
STS mortality risk %,
mean +SD
10.4 +6.1 10.7 +7.2 p¼0.97
LVEF%, mean +SD 41.7 +16.4 41.2 +17.8 p¼0.98
Zva: valvuloarterial impedance; ZvaPost/ZvaPre: valvuloarterial impedance index ratio; STS:
Society of Thoracic Surgeons; LVEF: left ventricular ejection fractionTCT-755
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Background: It is controversial whether female sex affects mortality after trans-
catheter aortic valve implantation (TAVI). Post-procedural AR  2 is a predictor of
mortality after (TAVI). Sex-differences in aortic and anatomic factors may affect post-
procedural AR. The aim of this study was a) to assess sex-differences in mortality after
TAVI, b) to investigate sex-differences in post-procedural AR and the interaction
between female sex and AR on mortality after TAVI.
Methods: This is a multicenter registry enrolling consecutive patients with symp-
tomatic severe aortic stenosis undergoing TAVI with the CoreValve system (92.8%)
or the Edwards SAPIEN valve system (7.2%). Multivariable Cox regression was
performed to compute hazard ratios (HR) with 95% conﬁdence interval (CI).
Results: A total of 656 patients, median age 83 yrs, (25th-75th percentile 79-86 yrs),
women (53.1%), men (46.9%) were enrolled. Body surface area (1.71 vs 1.81,
p<0.001) and annulus diameter (21.5 mm vs 23 mm, p<0.001) were signiﬁcantly
smaller in women than in men. Procedural success was similar in women as compared
to men (97.9% vs 96.7% in men, p¼0.32). Post-procedural AR  2 was signiﬁcantly
less frequent in women than in men (20.9% vs 29.6%, p¼0.01). After a median
follow-up of 372 days, all-cause mortality tended to be lower in women than in men
(20.7% vs 26.6%, logrank p¼0.10), while it was signiﬁcantly higher in patients with
AR  2 than in those without (34.8% vs 19.7%, logrank P<0.001). At multivariable
Cox regression post-procedural AR  2 (HR1.73, 95% conﬁdence interval (CI)
1.22-2.43, p¼0.002), but not female sex (p¼0.17) was an independent predictor of all-
cause death. AR  2 was a signiﬁcant predictor of all-cause death among men (HR
2.96, p<0.001), but not among women (HR 0.86, p¼0.60; p for interaction 0.002).
Conclusions: Postprocedural AR  2, but not female sex, is an independent predictor
of all-cause mortality at mid-term follow-up. AR  2 occurs less frequently among
women, and its prognostic impact is restricted to men.
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Background: Valvuloarterial impedance (Zva) is an index assessing global left
ventricular (LV) afterload that has shown to be a predictor of mortality in patients with
aortic stenosis (AS). We set out to evaluate whether improvement of Zva immediately
after balloon aortic valvuloplasty (BAV) can predict short term outcomes in high
surgical risk patients with severe AS evaluated for TAVI.B230 JACC Vol 62/18/Suppl B j October 27–NovemberMethods: 85 consecutive patients with severe AS underwent BAV. The prognostic
effectiveness of a new Zva index ratio, deﬁned as the ratio of the post-BAV Zva to the
pre-BAV Zva (post-Zva/pre-Zva), for 6-month endpoint event was evaluated in
patients not eligible for surgical valve replacement. Central systolic arterial pressure
(averaged from at least 3 measurements), mean transvalvular pressure gradient and
stroke volume index were obtained using invasive measurements.
Results: The postZva/preZva index ratio is a good predictor for 6-month endpoint
event. A cutoff value <0.85 was strongly associated with poor survival at 6 months.
Zva-derived measurements were similar between both groups with postZva/preZva
<0.85 and 0.85.Conclusions: Assessment of global LV hemodynamic load before and after BAV as
measured by the postZva/preZva index ratio may provide additional risk information
in high risk patients with severe AS evaluated for TAVR.
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Background: As the application of transcatheter aortic valve (TAV) implantation
moves towards intermediate or low risk patients, TAV durability will be a greater
concern. Current TAVs employ thin tissue leaﬂets, have limited or no stent-tip
deﬂection, and often exhibit "pinwheeled" leaﬂets due to abnormal deployment. These
factors are known to increase stress and limit the durability of surgical pericardial
valves. In this study, we present an elegant leaﬂet design of TAVs with chordal
reinforcement (Chord-TAVs) that can mitigate leaﬂet stress concentrations and
enhance overall valve durability.
Methods: Optimal designs of Chord-TAVs were obtained through computational
modeling. Chord-TAVs were fabricated from glutaraldehyde-treated thin bovine peri-
cardium sewn onto size 23woven nitinol stents. The leaﬂet strain distributions of Chord-
TAVs were measured from a static pressurization test. The Chord-TAVs were then
subjected to hydrodynamics and accelerated wear testing (AWT) per ISO-5840:2005.
Results: OptimizedChord-TAVs reduced simulated leaﬂet peak stress by 43%compared
to a chordless TAV and was comparable to simulated surgical CEP stress. The physical1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
